Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

Sofie Van Binnebeek(KU Leuven), Christophe M. Deroose(KU Leuven), B Vanbilloen(KU Leuven), Kris Bogaerts(Hasselt University), Felix M. Mottaghy(College Board), Karin Haustermans(Radboud University Nijmegen), Christelle Terwinghe(KU Leuven), Michel Koole(KU Leuven), Kristof Baete(KU Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Luc Mortelmans(KU Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Alfons Verbruggen(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
European Journal of Nuclear Medicine and Molecular Imaging
March 25, 2014
10.1007/s00259-013-2670-x
Cited by 30

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k